Rosuvastatin
| Rosuvastatin | |
|---|---|
| Salts [] | |
|---|---|
| Sodium rosuvastatin | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 481.50 g/mol [1] |
| Solubility | Sparingly soluble in water [1] |
| Predicted LogP | 1.6 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C22H28FN3O6S |
| IUPAC name | (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid |
| SMILES | CC(C)C1=NC(=NC(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C |
| InChI | InChI=1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1 |
| InChIKey | BPRHUIZQVSMCRT-VEUZHWNKSA-N |
| CAS number | 287714-41-4 |
| UNII | 413KH5ZJ73 |
| PubChem CID | 446157 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 19 hours |
| Metabolism | Liver: CYP2C9 (major) and CYP2C19-mediated; ~10% metabolized |
| Excretion | Feces (90%) |
| Routes of administration | Oral (by mouth) |
Rosuvastatin (also known as Creston, X-Plended, Rosuvastatina, Zd-4522, Zd4522, rosuvastatinum, C10aa07, rosuvastatine, Rosuvastatin Acid or Creston (TN) and brand names including Crestor) is a substance of the carboxylic acid class.
Chemistry
Salts []
Stereochemistry []
Rosuvastatin is a single defined stereoisomer (optical activity ( + )).
Druglikeness
Lipinski's rule of five
Rosuvastatin matches Lipinski's rule of five.Pharmacology
ATC Classification
- cardiovascular system (C)
- lipid modifying agents (C10)
- lipid modifying agents, plain (C10A)
- hmg coa reductase inhibitors (C10AA)
- (C10AA07)
- rosuvastatin (C10AA07)
MeSH Classification
Mechanism of action []
Rosuvastatin is a statin medication and a competitive inhibitor of the enzyme HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, which catalyzes the conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol biosynthesis. Rosuvastatin acts primarily in the liver, where decreased hepatic cholesterol concentrations stimulate the upregulation of hepatic low density lipoprotein (LDL) receptors which increases hepatic uptake of LDL. Rosuvastatin also inhibits hepatic synthesis of very low density lipoprotein (VLDL). The overall effect is a decrease in plasma LDL and VLDL. In vitro and in vivo animal studies also demonstrate that rosuvastatin exerts vasculoprotective effects independent of its lipid-lowering properties, also known as the pleiotropic effects of statins. This includes improvement in endothelial function, enhanced stability of atherosclerotic plaques, reduced oxidative stress and inflammation, and inhibition of the thrombogenic response. Statins have also been found to bind allosterically to β2 integrin function-associated antigen-1 (LFA-1), which plays an important role in leukocyte trafficking and in T cell activation. Rosuvastatin exerts an anti-inflammatory effect on rat mesenteric microvascular endothelium by attenuating leukocyte rolling, adherence and transmigration. The drug also modulates nitric oxide synthase (NOS) expression and reduces ischemic-reperfusion injuries in rat hearts. Rosuvastatin increases the bioavailability of nitric oxide by upregulating NOS and by increasing the stability of NOS through post-transcriptional polyadenylation. It is unclear as to how rosuvastatin brings about these effects though they may be due to decreased concentrations of mevalonic acid. [1]
Interactions []
Medical side effects []
76 side effects listed on drug labels in SIDER 4.1 (rosuvastatin).
- Headache
- Dizziness
- Arthralgia
- Musculoskeletal discomfort
- Myalgia
- Nausea
- Constipation
- Diabetes mellitus
- Asthenia
- Abdominal pain
- Gastrointestinal pain
- Dermatitis
- Rash
- Pruritus
- Urticaria
- Amnesia
- Memory loss
- Angioedema
- Arrhythmia
- Mental disorder
- Breast disorder
- Confusional state
- Feeling abnormal
- Depression
- Gynaecomastia
- Blood disorder
- Hepatitis
- Hypersensitivity
- Jaundice
- Renal failure acute
- Myopathy
- Musculoskeletal disorder
- Myoglobinuria
- Myoglobin urine present
- Myositis
- Nightmare
- Pancreatitis
- Neuropathy peripheral
- Rhabdomyolysis
- Thrombocytopenia
- Hepatic failure
- Muscular weakness
- Memory impairment
- Forgetfulness
- Hepatobiliary disease
- Muscle swelling
- Cognitive disorder
- Drug interaction
- Sleep disorder
- Insomnia
- Immune-mediated necrotising myopathy
- Nervous system disorder
- Bronchitis
- Infection
- Diarrhoea
- Dyspepsia
- Flatulence
- Gastroenteritis
- Haematuria
- Microscopic hematuria
- Influenza
- Nephropathy
- Hypertonia
- Pain
- Paraesthesia
- Pharyngitis
- Proteinuria
- Protein urine present
- Rhinitis
- Sinusitis
- Urinary tract infection
- Blood creatine phosphokinase increased
- Injury
- Hepatic enzyme increased
- Urine analysis abnormal
- Cough
Indications
- Alcoholism
- Atherosclerosis
- Cardiovascular disorder
- Cerebrovascular accident
- Coronary heart disease
- Diabetes mellitus
- Dyslipidaemia
- Heterozygous familial hypercholesterolemia
- Homozygous familial hypercholesterolaemia
- Hypercholesterolaemia
- Hyperlipidaemia
- Hypertriglyceridaemia
- Hypothyroidism
- Liver disorder
- Myocardial infarction
- Nephrotic syndrome
- Type II hyperlipidaemia
- Type III hyperlipidaemia
Subjective effects []
| 0xea / Rosuvastatin [] | |
|---|---|
Routes:
| |
Legal status []
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 446157, Rosuvastatin. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/446157
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Rosuvastatin. UNII: 413KH5ZJ73. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/413KH5ZJ73
Crestor Product information. Health Canada. 25 April 2012. https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=71404
Crestor 10mg film-coated tablets - Summary of Product Characteristics (SmPC). (emc). 29 September 2020. https://www.medicines.org.uk/emc/product/7559/smpc
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 16:00:43 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 16:00:39 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 16:00:39 |
| gsrs | ok | 2026-11-20 16:00:40 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0015230) | 2026-11-20 16:00:39 |
| kegg | ok | 2026-11-20 16:00:42 |
| pubchem | ok | 2026-11-20 16:00:38 |
| missing (no r/tripreports posts mention it) | 2026-11-20 16:00:39 | |
| sider | ok | 2026-11-20 16:00:39 |
| structure | ok | 2026-11-20 16:00:39 |
| wikipedia | ok | 2026-11-20 16:00:39 |